Lack of insight in schizophrenia: Impact on treatment adherence

Peter F. Buckley; Donna A. Wirshing; Prameet Bhushan; Joseph M. Pierre; Seth A. Resnick; William C. Wirshing

doi:10.2165/00023210-200721020-00004

Lack of insight in schizophrenia: Impact on treatment adherence

Peter F. Buckley, Donna A. Wirshing, Prameet Bhushan, Joseph M. Pierre, Seth A. Resnick, William C. Wirshing

Graduate Studies

Research output: Contribution to journal › Review article

116 Scopus citations

Abstract

People with schizophrenia commonly lack insight, that is, they are unaware of their illness and the consequences thereof. One of the most important consequences of lack of insight is a failure to recognise the need for treatment, leading to treatment nonadherence. With several scales that now enable objective measurement of insight, it is possible to examine correlates of insight change, including course of illness and treatment adherence. Specific interventions, both pharmacological and psychotherapeutic, have been developed to enhance illness insight and treatment adherence. The extent to which second-generation antipsychotic medications, including a recently released long-acting formulation, improve insight and/or enhance treatment adherence remains to be determined.

Original language	English (US)
Pages (from-to)	129-141
Number of pages	13
Journal	CNS Drugs
Volume	21
Issue number	2
DOIs	https://doi.org/10.2165/00023210-200721020-00004
State	Published - Feb 19 2007

Fingerprint

ASJC Scopus subject areas

Clinical Neurology
Psychiatry and Mental health
Pharmacology (medical)

Cite this

Buckley, P. F., Wirshing, D. A., Bhushan, P., Pierre, J. M., Resnick, S. A., & Wirshing, W. C. (2007). Lack of insight in schizophrenia: Impact on treatment adherence. CNS Drugs, 21(2), 129-141. https://doi.org/10.2165/00023210-200721020-00004

@article{df64186faa6f4d7981a767c2698aec5b,

title = "Lack of insight in schizophrenia: Impact on treatment adherence",

abstract = "People with schizophrenia commonly lack insight, that is, they are unaware of their illness and the consequences thereof. One of the most important consequences of lack of insight is a failure to recognise the need for treatment, leading to treatment nonadherence. With several scales that now enable objective measurement of insight, it is possible to examine correlates of insight change, including course of illness and treatment adherence. Specific interventions, both pharmacological and psychotherapeutic, have been developed to enhance illness insight and treatment adherence. The extent to which second-generation antipsychotic medications, including a recently released long-acting formulation, improve insight and/or enhance treatment adherence remains to be determined.",

author = "Buckley, {Peter F.} and Wirshing, {Donna A.} and Prameet Bhushan and Pierre, {Joseph M.} and Resnick, {Seth A.} and Wirshing, {William C.}",

year = "2007",

month = feb,

day = "19",

doi = "10.2165/00023210-200721020-00004",

language = "English (US)",

volume = "21",

pages = "129--141",

journal = "CNS Drugs",

issn = "1172-7047",

publisher = "Adis International Ltd",

number = "2",

}

TY - JOUR

T1 - Lack of insight in schizophrenia

T2 - Impact on treatment adherence

AU - Buckley, Peter F.

AU - Wirshing, Donna A.

AU - Bhushan, Prameet

AU - Pierre, Joseph M.

AU - Resnick, Seth A.

AU - Wirshing, William C.

PY - 2007/2/19

Y1 - 2007/2/19

N2 - People with schizophrenia commonly lack insight, that is, they are unaware of their illness and the consequences thereof. One of the most important consequences of lack of insight is a failure to recognise the need for treatment, leading to treatment nonadherence. With several scales that now enable objective measurement of insight, it is possible to examine correlates of insight change, including course of illness and treatment adherence. Specific interventions, both pharmacological and psychotherapeutic, have been developed to enhance illness insight and treatment adherence. The extent to which second-generation antipsychotic medications, including a recently released long-acting formulation, improve insight and/or enhance treatment adherence remains to be determined.

AB - People with schizophrenia commonly lack insight, that is, they are unaware of their illness and the consequences thereof. One of the most important consequences of lack of insight is a failure to recognise the need for treatment, leading to treatment nonadherence. With several scales that now enable objective measurement of insight, it is possible to examine correlates of insight change, including course of illness and treatment adherence. Specific interventions, both pharmacological and psychotherapeutic, have been developed to enhance illness insight and treatment adherence. The extent to which second-generation antipsychotic medications, including a recently released long-acting formulation, improve insight and/or enhance treatment adherence remains to be determined.

UR - http://www.scopus.com/inward/record.url?scp=33846967064&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846967064&partnerID=8YFLogxK

U2 - 10.2165/00023210-200721020-00004

DO - 10.2165/00023210-200721020-00004

M3 - Review article

C2 - 17284095

AN - SCOPUS:33846967064

VL - 21

SP - 129

EP - 141

JO - CNS Drugs

JF - CNS Drugs

SN - 1172-7047

IS - 2

ER -

Access to Document

10.2165/00023210-200721020-00004